APO Research
Talk to an analyst

APO RESEARCH · REPORT

Endometriosis Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Endometriosis Drugs Market Outlook and Growth Opportunities 2026

22 December 2025198 pages

Choose your research edition.

Industry ResearchEndometriosis Drugs Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Endometriosis Drugs Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Endometriosis Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Endometriosis Drugs Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Endometriosis Drugs Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Endometriosis Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Endometriosis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Endometriosis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Endometriosis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Endometriosis Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Endometriosis Drugs market include Takeda Pharmaceutical Company, Pfizer, AbbVie, AstraZeneca, ValiRx, Roivant Sciences, Repros Therapeutics, ObsEva and Neurocrine Biosciences, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Endometriosis Drugs market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Endometriosis Drugs and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Endometriosis Drugs revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Endometriosis Drugs market.

Endometriosis Drugs Segment by Company

Takeda Pharmaceutical Company

Pfizer

AbbVie

AstraZeneca

ValiRx

Roivant Sciences

Repros Therapeutics

ObsEva

Neurocrine Biosciences

Kissei Pharmaceutical

Evotec

Debiopharm Group

Astellas Pharma

Endometriosis Drugs Segment by Type

Chinese Herbs

Progestogens

Hormonal Therapy

Add-back Medication

Endometriosis Drugs Segment by Application

Research Institutes

Hospitals

Clinics

Endometriosis Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Endometriosis Drugs status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Endometriosis Drugs key companies, revenue, market share, and recent developments.

3. To split the Endometriosis Drugs breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Endometriosis Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Endometriosis Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Endometriosis Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Endometriosis Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Endometriosis Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Endometriosis Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Endometriosis Drugs industry.

Chapter 3: Detailed analysis of Endometriosis Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Endometriosis Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Endometriosis Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Endometriosis Drugs Industry Trends Table 2. Endometriosis Drugs Industry Drivers Table 3. Endometriosis Drugs Industry Opportunities and Challenges Table 4. Endometriosis Drugs Industry Restraints Table 5. Global Endometriosis Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Endometriosis Drugs Revenue Share by Company (2021-2026) Table 7. Global Endometriosis Drugs Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Endometriosis Drugs Key Company Manufacturing Base & Headquarters Table 9. Global Endometriosis Drugs Company, Product Type & Application Table 10. Global Endometriosis Drugs Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Endometriosis Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Chinese Herbs Table 15. Significant Companies of Progestogens Table 16. Significant Companies of Hormonal Therapy Table 17. Significant Companies of Add-back Medication Table 18. Global Endometriosis Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Endometriosis Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Endometriosis Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Endometriosis Drugs Sales Value Share by Type (2021-2026) Table 22. Global Endometriosis Drugs Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Research Institutes Table 24. Significant Companies of Hospitals Table 25. Significant Companies of Clinics Table 26. Global Endometriosis Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Endometriosis Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Endometriosis Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Endometriosis Drugs Sales Value Share by Application (2021-2026) Table 30. Global Endometriosis Drugs Sales Value Share by Application (2027-2032) Table 31. Global Endometriosis Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Endometriosis Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Endometriosis Drugs Sales Value Share by Region (2021-2026) Table 34. Global Endometriosis Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Endometriosis Drugs Sales Value Share by Region (2027-2032) Table 36. Global Endometriosis Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Endometriosis Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Endometriosis Drugs Sales Value Market Share by Country (2021-2026) Table 39. Global Endometriosis Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Endometriosis Drugs Sales Value Market Share by Country (2027-2032) Table 41. Takeda Pharmaceutical Company Company Information Table 42. Takeda Pharmaceutical Company Business Overview Table 43. Takeda Pharmaceutical Company Endometriosis Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Takeda Pharmaceutical Company Endometriosis Drugs Product Portfolio Table 45. Takeda Pharmaceutical Company Recent Development Table 46. Pfizer Company Information Table 47. Pfizer Business Overview Table 48. Pfizer Endometriosis Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Pfizer Endometriosis Drugs Product Portfolio Table 50. Pfizer Recent Development Table 51. AbbVie Company Information Table 52. AbbVie Business Overview Table 53. AbbVie Endometriosis Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. AbbVie Endometriosis Drugs Product Portfolio Table 55. AbbVie Recent Development Table 56. AstraZeneca Company Information Table 57. AstraZeneca Business Overview Table 58. AstraZeneca Endometriosis Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. AstraZeneca Endometriosis Drugs Product Portfolio Table 60. AstraZeneca Recent Development Table 61. ValiRx Company Information Table 62. ValiRx Business Overview Table 63. ValiRx Endometriosis Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. ValiRx Endometriosis Drugs Product Portfolio Table 65. ValiRx Recent Development Table 66. Roivant Sciences Company Information Table 67. Roivant Sciences Business Overview Table 68. Roivant Sciences Endometriosis Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Roivant Sciences Endometriosis Drugs Product Portfolio Table 70. Roivant Sciences Recent Development Table 71. Repros Therapeutics Company Information Table 72. Repros Therapeutics Business Overview Table 73. Repros Therapeutics Endometriosis Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Repros Therapeutics Endometriosis Drugs Product Portfolio Table 75. Repros Therapeutics Recent Development Table 76. ObsEva Company Information Table 77. ObsEva Business Overview Table 78. ObsEva Endometriosis Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. ObsEva Endometriosis Drugs Product Portfolio Table 80. ObsEva Recent Development Table 81. Neurocrine Biosciences Company Information Table 82. Neurocrine Biosciences Business Overview Table 83. Neurocrine Biosciences Endometriosis Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Neurocrine Biosciences Endometriosis Drugs Product Portfolio Table 85. Neurocrine Biosciences Recent Development Table 86. Kissei Pharmaceutical Company Information Table 87. Kissei Pharmaceutical Business Overview Table 88. Kissei Pharmaceutical Endometriosis Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Kissei Pharmaceutical Endometriosis Drugs Product Portfolio Table 90. Kissei Pharmaceutical Recent Development Table 91. Evotec Company Information Table 92. Evotec Business Overview Table 93. Evotec Endometriosis Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 94. Evotec Endometriosis Drugs Product Portfolio Table 95. Evotec Recent Development Table 96. Debiopharm Group Company Information Table 97. Debiopharm Group Business Overview Table 98. Debiopharm Group Endometriosis Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 99. Debiopharm Group Endometriosis Drugs Product Portfolio Table 100. Debiopharm Group Recent Development Table 101. Astellas Pharma Company Information Table 102. Astellas Pharma Business Overview Table 103. Astellas Pharma Endometriosis Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 104. Astellas Pharma Endometriosis Drugs Product Portfolio Table 105. Astellas Pharma Recent Development Table 106. Research Programs/Design for This Report Table 107. Authors List of This Report Table 108. Secondary Sources Table 109. Primary Sources List of Figures Figure 1. Endometriosis Drugs Product Image Figure 2. Global Endometriosis Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Endometriosis Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Endometriosis Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Chinese Herbs Image Figure 8. Progestogens Image Figure 9. Hormonal Therapy Image Figure 10. Add-back Medication Image Figure 11. Global Endometriosis Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Endometriosis Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Endometriosis Drugs Sales Value Share by Type (2021-2032) Figure 14. Research Institutes Image Figure 15. Hospitals Image Figure 16. Clinics Image Figure 17. Global Endometriosis Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Endometriosis Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Endometriosis Drugs Sales Value Share by Application (2021-2032) Figure 20. Global Endometriosis Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Endometriosis Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Endometriosis Drugs Sales Value (2021-2032) & (US$ Million) Figure 23. North America Endometriosis Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Endometriosis Drugs Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Endometriosis Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Endometriosis Drugs Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Endometriosis Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Endometriosis Drugs Sales Value (2021-2032) & (US$ Million) Figure 29. South America Endometriosis Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Endometriosis Drugs Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Endometriosis Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Endometriosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Endometriosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Endometriosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Endometriosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Endometriosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Endometriosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Endometriosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Endometriosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Endometriosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Endometriosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Endometriosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Endometriosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Endometriosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Endometriosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Endometriosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Endometriosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Endometriosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Endometriosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Endometriosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Endometriosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Endometriosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Endometriosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Endometriosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Endometriosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Endometriosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Endometriosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Endometriosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Endometriosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Endometriosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Endometriosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Endometriosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Endometriosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Endometriosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Endometriosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Endometriosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Endometriosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Endometriosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Endometriosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Endometriosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Endometriosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Endometriosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Endometriosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Endometriosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Endometriosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Endometriosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Endometriosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Endometriosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Endometriosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Endometriosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Endometriosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Endometriosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Endometriosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Endometriosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Endometriosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Endometriosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Endometriosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Endometriosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Endometriosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Endometriosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Endometriosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Endometriosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Endometriosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Endometriosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Endometriosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Endometriosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Endometriosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Endometriosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Endometriosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Endometriosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Endometriosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Endometriosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Endometriosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Endometriosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Endometriosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Endometriosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Endometriosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Endometriosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Endometriosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Endometriosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Endometriosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Endometriosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Endometriosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Endometriosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Endometriosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Chinese Herbs
  • Progestogens
  • Hormonal Therapy
  • Add-back Medication
Applications
  • Research Institutes
  • Hospitals
  • Clinics
Companies covered
  • Takeda Pharmaceutical Company
  • Pfizer
  • AbbVie
  • AstraZeneca
  • ValiRx
  • Roivant Sciences
  • Repros Therapeutics
  • ObsEva
  • Neurocrine Biosciences
  • Kissei Pharmaceutical
  • Evotec
  • Debiopharm Group
  • Astellas Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Endometriosis Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Endometriosis Drugs Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Endometriosis Drugs Market Dynamics
  1. 2.1 Endometriosis Drugs Industry Trends
  2. 2.2 Endometriosis Drugs Industry Drivers
  3. 2.3 Endometriosis Drugs Industry Opportunities and Challenges
  4. 2.4 Endometriosis Drugs Industry Restraints
3 Endometriosis Drugs Market by Company
  1. 3.1 Global Endometriosis Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Endometriosis Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Endometriosis Drugs Company Ranking (2024-2026)
  4. 3.4 Global Endometriosis Drugs Company Manufacturing Base and Headquarters
  5. 3.5 Global Endometriosis Drugs Company Product Type and Application
  6. 3.6 Global Endometriosis Drugs Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Endometriosis Drugs Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Endometriosis Drugs Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Endometriosis Drugs Market by Type
  1. 4.1 Endometriosis Drugs Type Introduction
  2. 4.1.1 Chinese Herbs
  3. 4.1.2 Progestogens
  4. 4.1.3 Hormonal Therapy
  5. 4.1.4 Add-back Medication
  6. 4.2 Global Endometriosis Drugs Sales Value by Type
  7. 4.2.1 Global Endometriosis Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Endometriosis Drugs Sales Value by Type (2021-2032)
  9. 4.2.3 Global Endometriosis Drugs Sales Value Share by Type (2021-2032)
5 Endometriosis Drugs Market by Application
  1. 5.1 Endometriosis Drugs Application Introduction
  2. 5.1.1 Research Institutes
  3. 5.1.2 Hospitals
  4. 5.1.3 Clinics
  5. 5.2 Global Endometriosis Drugs Sales Value by Application
  6. 5.2.1 Global Endometriosis Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Endometriosis Drugs Sales Value by Application (2021-2032)
  8. 5.2.3 Global Endometriosis Drugs Sales Value Share by Application (2021-2032)
6 Endometriosis Drugs Regional Value Analysis
  1. 6.1 Global Endometriosis Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Endometriosis Drugs Sales Value by Region (2021-2032)
  3. 6.2.1 Global Endometriosis Drugs Sales Value by Region: 2021-2026
  4. 6.2.2 Global Endometriosis Drugs Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Endometriosis Drugs Sales Value (2021-2032)
  7. 6.3.2 North America Endometriosis Drugs Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Endometriosis Drugs Sales Value (2021-2032)
  10. 6.4.2 Europe Endometriosis Drugs Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Endometriosis Drugs Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Endometriosis Drugs Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Endometriosis Drugs Sales Value (2021-2032)
  16. 6.6.2 South America Endometriosis Drugs Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Endometriosis Drugs Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Endometriosis Drugs Sales Value Share by Country, 2025 VS 2032
7 Endometriosis Drugs Country-level Value Analysis
  1. 7.1 Global Endometriosis Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Endometriosis Drugs Sales Value by Country (2021-2032)
  3. 7.2.1 Global Endometriosis Drugs Sales Value by Country (2021-2026)
  4. 7.2.2 Global Endometriosis Drugs Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Endometriosis Drugs Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Endometriosis Drugs Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Endometriosis Drugs Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Endometriosis Drugs Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Endometriosis Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Endometriosis Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Endometriosis Drugs Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Endometriosis Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Endometriosis Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Endometriosis Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Endometriosis Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Endometriosis Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Endometriosis Drugs Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Endometriosis Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Endometriosis Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Endometriosis Drugs Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Endometriosis Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Endometriosis Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Endometriosis Drugs Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Endometriosis Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Endometriosis Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Endometriosis Drugs Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Endometriosis Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Endometriosis Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Endometriosis Drugs Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Endometriosis Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Endometriosis Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Endometriosis Drugs Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Endometriosis Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Endometriosis Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Endometriosis Drugs Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Endometriosis Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Endometriosis Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Endometriosis Drugs Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Endometriosis Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Endometriosis Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Endometriosis Drugs Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Endometriosis Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Endometriosis Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Endometriosis Drugs Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Endometriosis Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Endometriosis Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Endometriosis Drugs Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Endometriosis Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Endometriosis Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Endometriosis Drugs Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Endometriosis Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Endometriosis Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Endometriosis Drugs Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Endometriosis Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Endometriosis Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Endometriosis Drugs Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Endometriosis Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Endometriosis Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Endometriosis Drugs Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Endometriosis Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Endometriosis Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Endometriosis Drugs Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Endometriosis Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Endometriosis Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Endometriosis Drugs Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Endometriosis Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Endometriosis Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Endometriosis Drugs Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Endometriosis Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Endometriosis Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Endometriosis Drugs Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Endometriosis Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Endometriosis Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Endometriosis Drugs Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Endometriosis Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Endometriosis Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Endometriosis Drugs Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Endometriosis Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Endometriosis Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Endometriosis Drugs Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Endometriosis Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Endometriosis Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Endometriosis Drugs Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Endometriosis Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Endometriosis Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Endometriosis Drugs Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Endometriosis Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Endometriosis Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda Pharmaceutical Company
  2. 8.1.1 Takeda Pharmaceutical Company Company Information
  3. 8.1.2 Takeda Pharmaceutical Company Business Overview
  4. 8.1.3 Takeda Pharmaceutical Company Endometriosis Drugs Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Pharmaceutical Company Endometriosis Drugs Product Portfolio
  6. 8.1.5 Takeda Pharmaceutical Company Recent Developments
  7. 8.2 Pfizer
  8. 8.2.1 Pfizer Company Information
  9. 8.2.2 Pfizer Business Overview
  10. 8.2.3 Pfizer Endometriosis Drugs Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Pfizer Endometriosis Drugs Product Portfolio
  12. 8.2.5 Pfizer Recent Developments
  13. 8.3 AbbVie
  14. 8.3.1 AbbVie Company Information
  15. 8.3.2 AbbVie Business Overview
  16. 8.3.3 AbbVie Endometriosis Drugs Revenue and Gross Margin (2021-2026)
  17. 8.3.4 AbbVie Endometriosis Drugs Product Portfolio
  18. 8.3.5 AbbVie Recent Developments
  19. 8.4 AstraZeneca
  20. 8.4.1 AstraZeneca Company Information
  21. 8.4.2 AstraZeneca Business Overview
  22. 8.4.3 AstraZeneca Endometriosis Drugs Revenue and Gross Margin (2021-2026)
  23. 8.4.4 AstraZeneca Endometriosis Drugs Product Portfolio
  24. 8.4.5 AstraZeneca Recent Developments
  25. 8.5 ValiRx
  26. 8.5.1 ValiRx Company Information
  27. 8.5.2 ValiRx Business Overview
  28. 8.5.3 ValiRx Endometriosis Drugs Revenue and Gross Margin (2021-2026)
  29. 8.5.4 ValiRx Endometriosis Drugs Product Portfolio
  30. 8.5.5 ValiRx Recent Developments
  31. 8.6 Roivant Sciences
  32. 8.6.1 Roivant Sciences Company Information
  33. 8.6.2 Roivant Sciences Business Overview
  34. 8.6.3 Roivant Sciences Endometriosis Drugs Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Roivant Sciences Endometriosis Drugs Product Portfolio
  36. 8.6.5 Roivant Sciences Recent Developments
  37. 8.7 Repros Therapeutics
  38. 8.7.1 Repros Therapeutics Company Information
  39. 8.7.2 Repros Therapeutics Business Overview
  40. 8.7.3 Repros Therapeutics Endometriosis Drugs Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Repros Therapeutics Endometriosis Drugs Product Portfolio
  42. 8.7.5 Repros Therapeutics Recent Developments
  43. 8.8 ObsEva
  44. 8.8.1 ObsEva Company Information
  45. 8.8.2 ObsEva Business Overview
  46. 8.8.3 ObsEva Endometriosis Drugs Revenue and Gross Margin (2021-2026)
  47. 8.8.4 ObsEva Endometriosis Drugs Product Portfolio
  48. 8.8.5 ObsEva Recent Developments
  49. 8.9 Neurocrine Biosciences
  50. 8.9.1 Neurocrine Biosciences Company Information
  51. 8.9.2 Neurocrine Biosciences Business Overview
  52. 8.9.3 Neurocrine Biosciences Endometriosis Drugs Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Neurocrine Biosciences Endometriosis Drugs Product Portfolio
  54. 8.9.5 Neurocrine Biosciences Recent Developments
  55. 8.10 Kissei Pharmaceutical
  56. 8.10.1 Kissei Pharmaceutical Company Information
  57. 8.10.2 Kissei Pharmaceutical Business Overview
  58. 8.10.3 Kissei Pharmaceutical Endometriosis Drugs Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Kissei Pharmaceutical Endometriosis Drugs Product Portfolio
  60. 8.10.5 Kissei Pharmaceutical Recent Developments
  61. 8.11 Evotec
  62. 8.11.1 Evotec Company Information
  63. 8.11.2 Evotec Business Overview
  64. 8.11.3 Evotec Endometriosis Drugs Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Evotec Endometriosis Drugs Product Portfolio
  66. 8.11.5 Evotec Recent Developments
  67. 8.12 Debiopharm Group
  68. 8.12.1 Debiopharm Group Company Information
  69. 8.12.2 Debiopharm Group Business Overview
  70. 8.12.3 Debiopharm Group Endometriosis Drugs Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Debiopharm Group Endometriosis Drugs Product Portfolio
  72. 8.12.5 Debiopharm Group Recent Developments
  73. 8.13 Astellas Pharma
  74. 8.13.1 Astellas Pharma Company Information
  75. 8.13.2 Astellas Pharma Business Overview
  76. 8.13.3 Astellas Pharma Endometriosis Drugs Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Astellas Pharma Endometriosis Drugs Product Portfolio
  78. 8.13.5 Astellas Pharma Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst